Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F10%3A7528" target="_blank" >RIV/00216208:11110/10:7528 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023728:_____/10:#0000091 RIV/00064165:_____/10:7528

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis

Popis výsledku v původním jazyce

Bone anabolic effects of teriparatide (TPTD, rhPTH (1-34) in postmenopausal women with osteoporosis may be blunted by previous exposure of bone to alendronate (ALN). Paired biopsies were obtained after tetracycline double labeling at baseline and after 24 months of TPTD treatment from 29 ALN-pretreated (64.5 +/- 16.4 months) and 16 treatment na?ve patients (TN). Biochemical markers were measured at baseline, during the treatment, or at study end. The level of increased bone formation after 24 months oftreatment with TPTD was similar in patients who were either treatment-naive or had lower bone turnover initially due to previous alendronate therapy. Elevated bone formation in postmenopausal women with osteoporosis was sustained over a 24-month period by TPTD. Biochemical markers of bone formation are a good surrogate for the assessment of TPTD effects.

Název v anglickém jazyce

Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis

Popis výsledku anglicky

Bone anabolic effects of teriparatide (TPTD, rhPTH (1-34) in postmenopausal women with osteoporosis may be blunted by previous exposure of bone to alendronate (ALN). Paired biopsies were obtained after tetracycline double labeling at baseline and after 24 months of TPTD treatment from 29 ALN-pretreated (64.5 +/- 16.4 months) and 16 treatment na?ve patients (TN). Biochemical markers were measured at baseline, during the treatment, or at study end. The level of increased bone formation after 24 months oftreatment with TPTD was similar in patients who were either treatment-naive or had lower bone turnover initially due to previous alendronate therapy. Elevated bone formation in postmenopausal women with osteoporosis was sustained over a 24-month period by TPTD. Biochemical markers of bone formation are a good surrogate for the assessment of TPTD effects.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Osteoporosis International

ISSN

0937-941X

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

—

Kód UT WoS článku

000285306900007

EID výsledku v databázi Scopus

—